Real-world evidence shows CDK4/6 inhibitors improve outcomes in hormone-positive metastatic breast cancer, suggesting better tolerance.
CDK4/6 inhibitors demonstrate similar responses and better tolerance in real-world evidence. Further studies are necessary to identify other predictive and resistance factors for the use of CDK4/6 inhibitors.
No takes yet. Share an insight, caveat, or question.
Sandeep et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: